New IPOPI Leaflets

,
Read more
/by

Early Bird Registration is now open for IPIC2025!

,

IPOPI is thrilled to open Early Bird registration for the 7th edition of the International Primary Immunodeficiency Congress (IPIC). Join us in Prague, Czech Republic, from November 5-7, 2025, for an exceptional opportunity to engage with global leaders in the field of primary immunodeficiencies. Don’t miss the chance to secure your spot at discounted rates!

IPIC is the leading international scientific meeting focusing on the clinical care of primary immunodeficiencies. At #IPIC2025, prominent international experts in the field will lead dynamic sessions fostering meaningful discussions on the latest advancements.

The programme will cover key topics such as:

  • AI tools in immunodeficiency management
  • Targeted therapies
  • Secondary immunodeficiencies
  • Complex persistent infections
  • Global trends around the world
  • Gene therapy in PID
  • Ethical considerations in genomics
  • Managing hepatic manifestations

Ensure your place at IPIC2025 by registering before the June 30, 2025, Early Bird deadline!

Register with early bird here.

/by

IPOPI’s 2023 Review of Activities and Achievements

, ,

In 2023, IPOPI made significant strides in improving primary immunodeficiencies (PIDs) care through impactful events, campaigns, and policy efforts, all aligned with our 2021-2025 strategic plan. A major highlight was the record-breaking International Primary Immunodeficiencies Congress (IPIC) in Rotterdam, which attracted nearly 900 attendees and fostered collaboration, advancing clinical care.

Throughout the year, we released a mini-documentary exploring primary and secondary immunodeficiencies, covering important aspects of diagnosis and treatment. Additionally, we published three new educational PID leaflets. We organised key events, including several EU PID Forums in the European Parliament, a successful African and Latin American regional meeting, and a well-attended national meeting in Jakarta, Indonesia.

In addition to these accomplishments, we strengthened our partnerships with global stakeholders, enhancing our collective advocacy efforts. Our work in addressing plasma safety standards and promoting equitable access to essential treatments has laid a solid foundation for future progress. We are committed to continuing our mission of empowering the PID community and driving meaningful change.

We hope you will enjoy reading this annual report, which highlights the most significant IPOPI initiatives, campaigns, and events in the previous year.

Explore the annual review

 

 

 

 

/by

Global Stakeholders Summit 2023 proceedings

,

Charting a course for global progress in PIDs by 2030 — proceedings from the IPOPI global multi-stakeholders’ summit (September 2023)

The IPOPI Global Multi-Stakeholders’ Summit in 2023 marked a pivotal moment for the Primary Immunodeficiency (PID) community, fostering forward-thinking discussions among stakeholders to shape the future priorities of PID care. In this article, we’re excited to share the comprehensive recommendations that emerged from this groundbreaking summit.

From pandemic preparedness to artificial intelligence tools

During the summit, various topics were discussed, including:

  • Personalised patient needs in immunoglobulin (Ig) therapy: This session explored avenues to improve Ig therapy through mechanistic insights and tailored Ig preparations or products according to patient-specific needs and local exposure to infectious agents, amongst others.
  • Pandemic preparedness: Reflections and lessons learned from the COVID-19 pandemic and the threat of antibiotics shortages and increasing antimicrobial resistance emphasized the need for representation of PID patients and other vulnerable populations throughout crisis and care management.
  • Diagnostic opportunities: Discussion also covered the complexities of PID diagnosis, addressing issues such as global diagnostic disparities, the integration of patient-reported outcome measures, and the potential of artificial intelligence to increase PID diagnosis rates and to enhance diagnostic precision.

Experts, physicians, scientists, patients, and representatives from across the globe came together during the summit to discuss the environment for PID patients in the upcoming decade. Through this collaborative effort, we aim to pave the way for improved PID diagnosis and care, by building upon the shared understanding of challenges, opportunities, and scenarios discussed during the summit.

Read the full article here.

This meeting was made possible thanks to the support from CSL Behring, Grifols and Takeda.

/by